All Updates

All Updates

icon
Filter
Partnerships
Evaxion Biotech teams up with Merck’s Keytruda
AI Drug Discovery
Oct 25, 2021
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Oct 25, 2021

Evaxion Biotech teams up with Merck’s Keytruda

Partnerships

  • Denmark-based AI immunology company Evaxion Biotech has entered into a clinical trial and supply agreement with Merck & Co’s subsidiary Kenilworth (known as MSD outside the US and Canada) for the clinical trial of melanoma therapies. 

  • Evaxion will conduct a Phase 2b clinical trial—expected to launch by the end of 2021—of its cancer immunotherapy EVX-01, combined with MSD’s anti-PD-1 (a protein found in T cells) therapy Keytruda, on patients with metastatic melanoma stages 3 and 4. MSD will supply the required Keytruda and continue collaborating as the study data evolves. 

  • Evaxion believes the partnership will improve the treatment and strengthen the evidence surrounding Evaxion’s platform and pipeline. It will also reduce the costs incurred to conduct the trial. The Phase 1/2a trial of EVX-01 to treat melanoma is currently ongoing.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.